Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2020

13.07.2020 | short review

San Antonio Breast Cancer Symposium 2019: human epidermal growth factor receptor 2(HER2)-positive breast cancer and image-guided biopsy to detect pathologic complete response (pCR)

verfasst von: M.D. Clemens Dormann

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

At the 2019 San Antonio Breast Cancer Symposium, new data on the management of heavily pretreated human epidermal growth factor receptor 2(HER2)-positive metastatic breast cancer were discussed. The phase 3 HER2CLIMB and the phase 2 DESTINY-Breast01 trials investigating tucatinib and trastuzumab deruxtecan, respectively, have met their primary endpoints.
In an early disease setting, four studies investigated whether image-guided biopsies could identify patients with a pathologic complete response (pCR) to neoadjuvant chemotherapy, thus allowing safe omission of surgery. As residual disease was missed in a significant number of cases, these trials could not confirm data from smaller previous studies.
Literatur
4.
Zurück zum Zitat Pheneger T, Bouhana K, Anderson D, et al. In vitro and in vivo activity of ARRY-380: a potent, small molecule inhibitor of ErbB2. Cancer Res. 2009;69:1795. Pheneger T, Bouhana K, Anderson D, et al. In vitro and in vivo activity of ARRY-380: a potent, small molecule inhibitor of ErbB2. Cancer Res. 2009;69:1795.
24.
Zurück zum Zitat Basik M, Cecchini RS, De Los Santos JF, et al. Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery. Cancer Res. 2020; https://​doi.​org/​10.​1158/​1538-7445.​SABCS19-GS5-05. CrossRef Basik M, Cecchini RS, De Los Santos JF, et al. Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery. Cancer Res. 2020; https://​doi.​org/​10.​1158/​1538-7445.​SABCS19-GS5-05. CrossRef
Metadaten
Titel
San Antonio Breast Cancer Symposium 2019: human epidermal growth factor receptor 2(HER2)-positive breast cancer and image-guided biopsy to detect pathologic complete response (pCR)
verfasst von
M.D. Clemens Dormann
Publikationsdatum
13.07.2020
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-020-00632-x

Weitere Artikel der Ausgabe 3/2020

memo - Magazine of European Medical Oncology 3/2020 Zur Ausgabe